Intrexon Corporation (NASDAQ:XON) and Five Prime Therapeutics Inc. (NASDAQ:FPRX) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intrexon Corporation	160.57M	5.50	509.34M	-0.81	0.00
Five Prime Therapeutics Inc.	49.87M	9.66	140.45M	-4.11	0.00

Table 1 demonstrates Intrexon Corporation and Five Prime Therapeutics Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of Intrexon Corporation and Five Prime Therapeutics Inc.

	Net Margins	Return on Equity	Return on Assets
Intrexon Corporation	-317.21%	-35%	-22.1%
Five Prime Therapeutics Inc.	-281.63%	-44.6%	-36.9%

Volatility & Risk

Intrexon Corporation is 138.00% more volatile than Standard & Poor’s 500 because the stock has a beta of 2.38. Five Prime Therapeutics Inc.’s 221.00% more volatile than Standard & Poor’s 500 which is a result of the 3.21 beta.

Liquidity

The Current Ratio of Intrexon Corporation is 3.4 while its Quick Ratio stands at 3.2. The Current Ratio of rival Five Prime Therapeutics Inc. is 10.5 and its Quick Ratio is has 10.5. Five Prime Therapeutics Inc. is better equipped to clear short and long-term obligations than Intrexon Corporation.

Analyst Recommendations

The Ratings and Recommendations for Intrexon Corporation and Five Prime Therapeutics Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Intrexon Corporation	0	0	0	0.00
Five Prime Therapeutics Inc.	0	0	1	3.00

Institutional & Insider Ownership

Intrexon Corporation and Five Prime Therapeutics Inc. has shares owned by institutional investors as follows: 86.7% and 88.4%. Insiders owned roughly 0.6% of Intrexon Corporation’s shares. Competitively, Five Prime Therapeutics Inc. has 2.4% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Intrexon Corporation	-51.18%	-45.95%	-57.36%	-73.55%	-67.91%	-36.7%
Five Prime Therapeutics Inc.	0.67%	7.11%	-6.3%	-14.3%	-41.5%	29.57%

For the past year Intrexon Corporation had bearish trend while Five Prime Therapeutics Inc. had bullish trend.

Summary

Five Prime Therapeutics Inc. beats on 7 of the 11 factors Intrexon Corporation.

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. The company serves health, food, energy, environment, and consumer sectors. Intrexon Corporation has collaboration and license agreements with Ares Trading S.A.; ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Thrive Agrobiotics, Inc.; Intrexon Energy Partners II, LLC; and others. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.